Dan Marks

Dan Marks is a Principal on the Venture Team at RA Capital Management. Dan’s primary responsibility at RA Capital is to identify compelling opportunities for investments in early stage companies and to help facilitate new company creation. Dan's focus has been on oncology investments, where he has worked with numerous RA Capital portfolio companies across cell therapies, ADCs, and engineered cytokines. Dan joined RA Capital in 2017, and holds a BS in Biology from Yale University and a PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences.